Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) has earned an average rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $29.50.
Several brokerages recently commented on SBPH. Jefferies Financial Group began coverage on Spring Bank Pharmaceuticals in a report on Tuesday. They set a “buy” rating and a $28.00 target price on the stock. Cantor Fitzgerald set a $35.00 target price on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 3rd. Finally, Piper Jaffray Companies began coverage on Spring Bank Pharmaceuticals in a report on Tuesday, August 14th. They set an “overweight” rating and a $25.00 target price on the stock.
In other Spring Bank Pharmaceuticals news, insider Martin J. Driscoll acquired 4,000 shares of the company’s stock in a transaction on Monday, August 13th. The shares were bought at an average cost of $12.02 per share, for a total transaction of $48,080.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 15.60% of the stock is owned by insiders.
Shares of NASDAQ SBPH traded up $0.46 during midday trading on Tuesday, hitting $14.36. The stock had a trading volume of 2,031 shares, compared to its average volume of 45,754. The firm has a market capitalization of $158.88 million, a P/E ratio of -7.74 and a beta of 0.18. Spring Bank Pharmaceuticals has a 1-year low of $10.63 and a 1-year high of $18.93.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its quarterly earnings data on Thursday, August 2nd. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.22. On average, equities analysts expect that Spring Bank Pharmaceuticals will post -1.89 earnings per share for the current fiscal year.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.